ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,621.99
-0.15%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. 89bio Inc (ETNB)

  7. 89bio Inc (ETNB) Noticias

ETNB

89bio (ETNB)

89bio Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ETNB
FechaHoraFuenteTítuloSímboloCompañía
31/05/202415:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ETNB89bio Inc
09/05/202415:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ETNB89bio Inc
01/03/202416:06Edgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405NASDAQ:ETNB89bio Inc
01/03/202416:03Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ETNB89bio Inc
23/02/202419:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ETNB89bio Inc
14/02/202410:32Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ETNB89bio Inc
08/12/202305:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ETNB89bio Inc
21/09/202308:07Dow Jones News89bio Gets FDA Breakthrough Designation for Pegozafermin in NASHNASDAQ:ETNB89bio Inc
09/06/202315:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ETNB89bio Inc
07/06/202316:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ETNB89bio Inc
05/06/202316:35Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:ETNB89bio Inc
25/04/202316:29Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:ETNB89bio Inc
24/04/202315:36Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ETNB89bio Inc
24/04/202315:34Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ETNB89bio Inc
24/03/202306:00GlobeNewswire Inc.89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common StockNASDAQ:ETNB89bio Inc
22/03/202316:06Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ETNB89bio Inc
22/03/202315:16GlobeNewswire Inc.89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:ETNB89bio Inc
15/03/202306:06Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ETNB89bio Inc
15/03/202305:25Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ETNB89bio Inc
14/02/202316:25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ETNB89bio Inc
14/02/202316:17Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ETNB89bio Inc
14/02/202315:33Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ETNB89bio Inc
10/02/202315:04Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:ETNB89bio Inc
31/01/202305:08Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:ETNB89bio Inc
04/01/202315:01GlobeNewswire Inc.89bio Provides Business Update and Outlook for 2023NASDAQ:ETNB89bio Inc
12/12/202217:30GlobeNewswire Inc.89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & HepatologyNASDAQ:ETNB89bio Inc
25/11/202203:04TipRanksAnalysts Say These 2 ‘Strong Buy’ Stocks Are Their Top Picks for 2023NASDAQ:ETNB89bio Inc
21/11/202205:21TipRanksAnalysts Offer Insights on Healthcare Companies: Altimmune (ALT), 89bio (ETNB) and Avadel Pharmaceuticals (AVDL)NASDAQ:ETNB89bio Inc
13/11/202222:05TipRanksBTIG Sticks to Its Buy Rating for 89bio (ETNB)NASDAQ:ETNB89bio Inc
13/11/202221:57TipRanks89bio (ETNB) Receives a Buy from SVB SecuritiesNASDAQ:ETNB89bio Inc
 Showing the most relevant articles for your search:NASDAQ:ETNB

Su Consulta Reciente

CCOM
OILBRENT
Brent Oil
FX
EURMXN
Euro vs MXN
AMEX
XLF
Financial Select Sector
USI
USTECH100
US Tech 100
NYSE
VZ
Verizon Communications
USOTC
ADDYY
Adidas (QX)
SPI
SP500
S&P 500
CCOM
US30
US 30
USOTC
RHHBY
Roche (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
ETHUSD
Ethereum
NASDAQ
NVDA
NVIDIA
NYSE
BAC
Bank of America
NYSE
NKE
Nike
USOTC
BASFY
BASF (QX)
AMEX
XLV
Health Care Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados